Germany's Merck Swaps CAR-T Rights For Equity In Intrexon, Focusing Its R&D
Executive Summary
Merck KGaA has rejigged a 2015 drug development deal with NASDAQ-listed Intrexon, swapping rights to potential CAR-T therapies for stock in the biology specialist.
You may also be interested in...
Finance Watch: Intrexon Reorganizes, Raises Cash And Becomes Precigen
The new year starts with a strategic shift by Intrexon. Also, Roivant and Sumitomo Dainippon launch Sumitovant, Melinta reorganizes through Chapter 11 bankruptcy, Acorda arranges debt relief and CF PharmTech raises a $90m series E round.
Deal Watch: Gilead Signs Two Deals In Two Days To Increase R&D Emphasis
As it moves away from virology, Gilead’s signs fibrosis collaboration with Scholar Rock. Novartis seeks to acquire CMDO that manufactures Kymriah, while Intrexon regains control of CAR-T program partnered with Merck KGAA. More deals from over the holiday period…
Merck KGaA Foresees Mid-2019 US Launch Of Oral MS Therapy Mavenclad
German Merck tells Scrip Mavenclad's long spell in the regulatory 'wilderness' allowed it to amass deep safety and efficacy data that should help the oral MS drug's commercial prospects.